Rein Therapeutics Inc. recently announced the adjournment of its 2025 annual meeting of stockholders, originally scheduled for June 24, 2025, due to the lack of a quorum. The meeting has been rescheduled to July 23, 2025, and will be held virtually. Rein Therapeutics, a biopharmaceutical company focused on developing medications for orphan pulmonary and fibrosis indications, is encouraging stockholders to participate and vote on the proposals detailed in their definitive proxy statement. The board of directors, led by Chairperson [First Name] [Last Name], is urging stockholders to vote in favor of all proposals. Proxies submitted prior to the adjournment will remain valid unless revoked or amended by stockholders. Voting can be modified via signed proxy or electronically until July 22, 2025. The meeting will be accessible online, providing an opportunity for shareholders to engage and cast their votes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.